Management of Candidemia

Publisher Website
Google Scholar
Abstract
Finding the optimal treatment for patients with candidemia has been a major source of frustration for physicians during the past decade. It is a tremendous challenge, since the infection is often an obstacle to successful therapy, and the cost in terms of health resources is high. The rate of candidemia has increased by more than 400 percent since the early 1980s, and candidemia currently accounts for 10 to 15 percent of hospital-acquired infections of the bloodstream.1 There is an increased awareness of the morbidity, mortality, and economic burden associated with candidemia in various groups of patients, including those without neutropenia. . . .